These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 28855009)

  • 1. AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's Disease.
    Glynn-Servedio BE; Ranola TS
    Consult Pharm; 2017 Sep; 32(9):511-518. PubMed ID: 28855009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
    Standridge JB
    Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What are the treatment options for patients with severe Alzheimer's disease?
    Voisin T; Reynish E; Portet F; Feldman H; Vellas B
    CNS Drugs; 2004; 18(9):575-83. PubMed ID: 15222774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationalizing therapeutic approaches in Alzheimer's disease.
    Grossberg GT
    CNS Spectr; 2005 Nov; 10(11 Suppl 18):17-21. PubMed ID: 16273026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
    Deardorff WJ; Grossberg GT
    Expert Opin Pharmacother; 2016 Sep; 17(13):1789-800. PubMed ID: 27450461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
    Yamada M
    Brain Nerve; 2023 May; 75(5):464-469. PubMed ID: 37194514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Memantine: the value of combined therapy].
    Molinuevo JL
    Rev Neurol; 2011 Jan; 52(2):95-100. PubMed ID: 21271549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
    Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
    Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H; Grossberg GT
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.
    Hyde C; Peters J; Bond M; Rogers G; Hoyle M; Anderson R; Jeffreys M; Davis S; Thokala P; Moxham T
    Age Ageing; 2013 Jan; 42(1):14-20. PubMed ID: 23179169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors.
    Shega JW; Ellner L; Lau DT; Maxwell TL
    J Palliat Med; 2009 Sep; 12(9):779-83. PubMed ID: 19622011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors.
    Shi X; Lin X; Hu R; Sun N; Hao J; Gao C
    Am J Alzheimers Dis Other Demen; 2016 Aug; 31(5):405-12. PubMed ID: 26769920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of memantine in the treatment of dementia.
    Rossom R; Adityanjee ; Dysken M
    Am J Geriatr Pharmacother; 2004 Dec; 2(4):303-12. PubMed ID: 15903287
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.